Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06700915 · ClinicalTrials.gov registry record · NA

A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and Metabolism

A NA study of Metabolism Disorder and Nutraceutical, sponsored by Ultimate International.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT06700915 is a NA study of Metabolism Disorder and Nutraceutical that is actively recruiting participants, run by Ultimate International. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06700915, a NA study of Metabolism Disorder and Nutraceutical, is actively recruiting participants, sponsored by Ultimate International.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This randomized, triple-blind, placebo-controlled study will evaluate the efficacy of Diaberine, a berberine-based nutraceutical, in aiding blood sugar regulation and metabolism in 80 participants over 24 weeks.

Interventions

  • DIETARY_SUPPLEMENT Diaberine
  • DIETARY_SUPPLEMENT Placebo Capsule

Study Locations (1)

California

  • Citruslabs - Santa Monica

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-10-03
Est. Completion 2025-05-01
Phase NA

Sponsor

Ultimate International

1 total trials

What the Registry Record Tells You About NCT06700915

The ClinicalTrials.gov registry entry for NCT06700915 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultimate International, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metabolism Disorder appearing as the primary indexed condition, and to 2 interventions - of which Diaberine is the first listed.

NCT06700915 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06700915 about?

NCT06700915 is a clinical study titled "A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and Metabolism". This randomized, triple-blind, placebo-controlled study will evaluate the efficacy of Diaberine, a berberine-based nutraceutical, in aiding blood sugar regulation and metabolism in 80 participants over 24 weeks.

What is the current status of trial NCT06700915?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-10-03. Estimated completion is 2025-05-01.

What conditions does trial NCT06700915 study?

This clinical trial studies the following conditions: Metabolism Disorder, Nutraceutical.

What interventions are being tested in trial NCT06700915?

The interventions under investigation include: Diaberine (DIETARY_SUPPLEMENT), Placebo Capsule (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06700915?

This trial is sponsored by Ultimate International, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06700915 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolism Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.